Mission Bio Inc., a precision medicine company, appointed Brian Kim CEO. With over two decades of experience in the life sciences industry, Kim brings a combination of scientific innovation and strategic business development to the company.

Kim brings experience in driving organizational transformation and large-scale commercial growth, along with deep knowledge of the life sciences sector, as Mission Bio aims to expand into clinical applications with biopharma partners.

As CEO of  Fortis Life Sciences, Kim founded and grew the company into a leading business-to-business provider of proprietary reagents for clinical customers. As managing director of the Biosearch Technologies division of LGC, a UK-based private equity-backed life sciences tools company, Kim spearheaded the expansion into diagnostics and therapeutic end markets, resulting in the successful sale of the company in 2020. As President of PerkinElmer’s Life Science and Tools division, he revitalized product innovation, revamped the commercial organization, and returned the business to growth.

“Brian’s experience in life sciences tools commercialization and clinical end markets fits exactly with Mission Bio’s vision to advance single cell multiomics into translational research and clinical applications,” said Stuart Essig, chairman of the board at Mission Bio. “He comes at an exciting stage in the company’s evolution when our technology is beginning to make measurable progress in helping improve patient health outcomes.”

Kim said, “As I step into my new role, my first objective is to support the amazing team and the growing body of customer applications built around the Tapestri platform. I am committed to the founding vision of establishing Mission Bio as an essential part of the new standard for personalized medicine and targeted therapies.”